Document is current

Article History

Received: 29 April 2021

Accepted: 17 July 2021

First Online: 6 August 2021

Declarations

:

: Dr. Hiltunen reports non-financial support from Pfizer (congress costs), outside the submitted work. Dr. Parmanne reports non-financial support from Novartis, Pfizer and Abbvie, outside the submitted work. Dr. Sokka-Isler reports non-financial support from DiaGraphIT, personal fees from Abbvie, BMS, Celgene, Medac, Merck, Novartis, Orion Pharma, Pfizer, Roche, Sandoz, UCB and Bohringer Ingelheim, outside the submitted work. Dr. Isomäki reports personal fees and non-financial support from Abbvie, personal fees from Lilly, Pfizer, personal fees and non-financial support from Roche, outside the submitted work. Dr. Kaipiainen-Seppänen reports non-financial support from Novartis and Pfizer, outside the submitted work. Dr. Pirilä reports personal fees from Mylan Finland, Novartis Finland, Abbvie Oy, Boeringer Ingelheim, Pfizer, Swedish Orphan Biotirum and Viatris, other support from Oriola Finland, Sanofi, Jansen Cilat and Eli Lilly Finland, outside the submitted work. Dr. Kauppi reports personal fees from Abbvie, Eli Lilly Finland, MSD, Novartis/Sandoz, Pfizer, Roche, UCB and Berlin-Chenie Menarini, outside the submitted work. Dr. Yli-Kerttula reports personal fees from MSD, Pfizer, BMS and Abbvie, outside the submitted work. Dr. Tuompo reports personal fees from Viatris, non-financial support from Novartis and Viatris, outside the submitted work. Dr. Relas reports personal fees from Abbvie, Celgene and Pfizer, outside the submitted work. Dr. Paalanen reports non-financial support from Celgene, Sandoz, non-financial support and other from Pfizer, personal fees and other from Orion Pharma, non-financial support and other support from MSD, non-financial support and other support from Medac, non-financial support and other support from Roche, non-financial support from Sanofi, outside the submitted work. Dr. Vidqvist reports personal fees (lecturer fees and advisory board): Abbvie, Boeringer-Ingelheim, Novartis, Pfizer and UCB. Dr. Tadesse reports non-financial support from Novartis, outside the submitted work. Dr. Borodina reports non-financial support from Novartis, Roche and Eli Lilly, outside the submitted work. Dr. Elfving reports personal fees from Abbvie (lecture fee) and Astra Zeneca (consultation fee), non-financial support from Pfizer and Mylan (congress costs), outside the submitted work. Dr. Rantalaiho reports congress grants from Mylan, Abbvie and Pfizer, and a study grant from BMS for NordStar trial, outside the submitted work. Dr. Jokiranta reports grants from Pfizer, during the conduct of the study; personal fees from Abbvie, Alexion Pharmaceuticals, Bristol- Myers Squibb, Eli Lilly Finland, Medac, Medscape, MSD, Novartis/Sandoz, Pfizer, Roche, Scopeful, Takeda, UCB, United Medix Laboratories and Tammer BioLab, outside the submitted work. Dr. Eklund reports grants from Pfizer, during the conduct of the study. PhD. Lamberg, Dr. Peltomaa, Dr Uutela, Dr. Taimen, Dr. Kortelainen, Dr. Asikainen, Dr. Ekman, Dr. Santisteban, Dr. Romu, Dr. Valleala, Dr. Leirisalo-Repo and Mr. Kautiainen have nothing to disclose.

: The study protocol was approved by the Ethical Review Board of the Joint Authority for the Hospital District of Helsinki and Uusimaa (108/13/03/01/2014).

: All the patients gave an informed written consent.

: All of the authors have given the permission for publication.